1. Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26(9 Suppl):S191–7.
2. Mead RJ, Shan N, Reiser HJ, et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22(3):185–212.
3. de Courssou J-BB, Durr A, Adams D, et al. Antisense therapies in neurological diseases. Brain. 2022;145(3):816–31.
4. Biogen MA Inc. QALSODY (tofersen) injection, for intrathecal use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf. Accessed 30 May 2023.
5. Biogen IP. Biogen exercises option with Ionis to develop and commercialize investigational treatment BIIB067 for a subtype of familial amyotrophic lateral sclerosis (ALS) based on positive phase 1 data [media release]. 6 Dec 2018. http://www.biogen.com.